Наукові роботи
Наукові роботи
- Nov 10 - 13, 2024
Exposure-Response Relationship of Dostarlimab in Combination with Platinum-Containing Chemotherapy in Primary Advanced or Recurrent Endometrial Cancer: Results From the Second Interim Analysis of Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Abstract - International Society of Pharmacometrics - International Society of Pharmacometrics - 15th American Conference on Pharmacometrics (ACoP 15)
- Oct 4, 2024
Випадок пухлини Бреннера у пацієнтки репродуктивного віку з ожирінням
Ужгород, Україна: III Міжнародна наукова конференція «Розвиток наук в умовах нової реальності: проблеми та перспективи»
- Sep 30, 2024
Український радіологічний та онкологічний журнал. 2024. Т. 32. No 3. С. 417–425
- Sep 30, 2024
Brenner tumor in reproductive-age women with obesity: a clinical and morphological case analysis
Ukrainian journal of radiology and oncology. 2024;32(3):417–425
- Feb 22-24, 2024
ENCORE: Dostarlimab for primary advanced or recurrent endometrial cancer: Blinded independent central review (BICR)
Japanese Society of Medical Oncology - 21st Scientific Meeting, Nagoya, Japan
- March 07 - 10, 2024
The difference between progression-free survival 2 and progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6- NSGO/GOG-3031/RUBY Trial
European Society of Gynaecological Oncology - 25th International Meeting, Barcelona, Spain
- March 07 - 10, 2024
Progression-free survival 2- progression- free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone
European Society of Gynaecological Oncology, 25th International Meeting, Barcelona, Spain
- 2024
Patient-reported outcomes in the RUBY trial in patients with primary advanced or recurrent endometrial cancer
International Journal of Gynecological Cancer
- 2024
HOPA Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin- paclitaxel in the ENGOT- EN6/GOG-3031/RUBY trial (ESGO 2023)
INDUSTRY ENCORE Hematology/Oncology Pharmacy Association - 20th Annual Conference
- 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in Part 1 of RUBY
British Journal of Clinical Pharmacology (Document Number - DV-001845)
- Sep 28 - Oct 1, 2023
STREAM-I/AGO-OP.11/ENGOT- En22: Evaluation Of Preoperative Clinical And Translational Selection Criteria For Cytoreductive Surgery In Endometrial Cancer
Step 1 Of The STREAM (Surgical Treatment In Advanced And Recurrent Endometrial Cancer Management) Initiative - European Society of Gynaecological Oncology - 24th International Meeting, Istambul, Turkey
- Nov 5-8, 2023
International Society of Pharmacometrics 14th American Conference on Pharmacometrics, Maryland, USA
- Sep 28 - Oct 1, 2023
Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
European Society of Gynaecological Oncology 24th International Meeting, Istambul, Turkeу
- Jan 3, 2023
American Society of Clinical Oncology 59th Annual Meeting, Chicago,IL